YS Life Science is an API manufacturer based in South Korea. It holds 8 active US drug master files and 2 valid CEPs across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 February 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hwaseong-si, South Korea | Not on file |
| South, South Korea | 3005877120 |
| Molecule | Regulators | Docs |
|---|---|---|
| Cabergoline | EDQM, SFDA (Saudi Arabia) | 2 |
| Iloprost | SFDA (Saudi Arabia), US FDA | 2 |
| Latanoprost | EDQM, US FDA | 2 |
| Bimatoprost | US FDA | 1 |
| Latanoprostene Bunod | US FDA | 1 |
| Lubiprostone | US FDA | 1 |
| Misoprostol | US FDA | 1 |
| Travoprost | US FDA | 1 |
| Treprostinil | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. YS Life Science comes back tiered against every other supplier able to file there.
Start for free